Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.10
Nov 16 • 3:59 PM ET Dollar change-0.22 Percentage change(-9.48%)
Aftermarket Close
2.13
Aftermarket • 7:54 PM ET Dollar change+0.03 Percentage change(1.37%)
Index
RUT
Market Cap
267.48M
Enterprise Value
207.64M
Income
-58.58M
Sales
0.42M
Book/sh
0.92
Cash/sh
0.68
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
130
IPO
Aug 07, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
636.86
P/B
2.29
P/C
3.09
P/FCF
-
EV/EBITDA
-
EV/Sales
494.38
Quick Ratio
9.25
Current Ratio
9.25
Debt/Eq
0.23
LT Debt/Eq
0.19
Option/Short
Yes / Yes
EPS (ttm)
-0.46
EPS next Y
-0.48
EPS next Q
-0.14
EPS this Y
-3.19%
EPS next Y
0.00%
EPS next 5Y
1.68%
EPS past 3/5Y
-0.17% 0.21%
Sales past 3/5Y
- -
EPS Y/Y TTM
7.31%
Sales Y/Y TTM
-
EPS Q/Q
-14.33%
Sales Q/Q
-
Insider Own
41.98%
Insider Trans
-8.55%
Inst Own
28.61%
Inst Trans
-4.54%
ROA
-33.49%
ROE
-41.01%
ROIC
-42.10%
Gross Margin
-1242.22%
Oper. Margin
-15105.66%
Profit Margin
-13816.75%
SMA20
-17.30%
SMA50
10.83%
SMA200
-1.43%
Trades
Shs Outstand
127.33M
Shs Float
73.90M
52W High
4.31 -51.28%
52W Low
0.84 149.67%
Volatility
8.95% 16.94%
ATR (14)
0.33
RSI (14)
46.00
Beta
0.67
Rel Volume
0.71
Avg Volume
5.87M
Volume
4,157,910
Perf Week
-11.76%
Perf Month
1.94%
Perf Quarter
146.54%
Perf Half Y
-11.02%
Perf YTD
7.69%
Perf Year
16.67%
Perf 3Y
-28.93%
Perf 5Y
-58.58%
Perf 10Y
-
Prev Close
2.32
Price
2.10
Change %
-9.48%
Consensus
Strong Buy
Avg. Price Target
$4.00
Implied Upside
+90.5%
Analysts7incl. previous ratings
Rating Distribution4 Buy · 2 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 29, 2026Initiated
RRoth Capital
Buy$3.50+66.7%
Sep 09, 2026Initiated
LLeerink Partners
Outperform$4+90.5%
Dec 05, 2024Downgrade
GS logoGGoldman
Neutral → Sell$1.75-16.7%
Jun 27, 2024Initiated
GGuggenheim
Buy$6+185.7%
Jun 03, 2024Resumed
JEF logoJJefferies
Hold$3+42.9%
Jan 06, 2022Initiated
MS logoMMorgan Stanley
Equal-Weight$8+281.0%
Nov 02, 2021Initiated
CCowen
Outperform
Aug 04, 2021Initiated
GS logoGGoldman
Neutral$10+376.2%
Jul 13, 2021Initiated
JEF logoJJefferies
Buy$13+519.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AH Equity Partners Bio II, L.L10% OwnerJun 02 '26Sale2.355,000,00011,750,000971,885Jun 04 04:53 PM
Patel Sujal MCEO, President, and SecretaryMar 04 '26Buy2.6125,00065,23810,366,721Mar 04 06:37 PM
Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal M. Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
Co-FounderMr. Sujal M. Patel
Co-FounderDr. Parag Mallick Ph.D.
CFO & TreasurerMs. Anna Mowry
General CounselMr. Matthew B. Murphy ESQ.
Vice President of Global SalesMs. Amber Faust